Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787800 · ClinicalTrials.gov registry record · Phase 4
The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock
A Phase 4 study of Atrial Fibrillation and Ventricular Tachycardia, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT00787800 is a Phase 4 study of Atrial Fibrillation and Ventricular Tachycardia that has completed, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00787800, a Phase 4 study of Atrial Fibrillation and Ventricular Tachycardia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
The RAPTURE Study will determine whether dual chamber defibrillators with atrial prevention and termination therapies, minimized ventricular pacing, and remote monitoring will reduce the rate of inappropriate shocks and improve quality of life compared to optimally programmed back-up pacing only single chamber ICDs when used for primary prevention of sudden cardiac death
Conditions Studied
Interventions
- DEVICE Dual Chamber ICD
- DEVICE Single Chamber ICD
Study Locations (4)
Other
- Carmel Medical Center - Haifa
- Sheba Medical Center - Ramat Gan
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787800
The ClinicalTrials.gov registry entry for NCT00787800 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Dual Chamber ICD is the first listed.
NCT00787800 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00787800 about?
NCT00787800 is a clinical study titled "The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock". The RAPTURE Study will determine whether dual chamber defibrillators with atrial prevention and termination therapies, minimized ventricular pacing, and remote monitoring will reduce the rate of inappropriate shocks and improve quality of life compared to optimally programmed back-up pacing only sin...
What is the current status of trial NCT00787800?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-11. Estimated completion is 2011-12.
What conditions does trial NCT00787800 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Ventricular Tachycardia, Ventricular Fibrillation, Supraventricular Tachycardia.
What interventions are being tested in trial NCT00787800?
The interventions under investigation include: Dual Chamber ICD (DEVICE), Single Chamber ICD (DEVICE).
Who is sponsoring clinical trial NCT00787800?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00787800 being conducted?
This trial has 4 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.